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Chapter 1: Importance of Autophagy
1.1 Introduction
Autophagy is an intracellular process that keeps the cell intact while disposing of no
longer functional organelles, misfolded/degraded proteins, as well as bacteria and viruses (2),
using lysosomes to remove the unwanted cellular debris. Autophagy is a normal function of
all cells required to maintain homeostasis by breaking down unnecessary cell components
into useful metabolites. Autophagy also serves as a cell survival mechanism allowing cells to
survive with limited nutrients and avoid mechanisms of apoptosis (7). Autophagy can be
broken down into selective and non-selective. Non-selective autophagy is the random
sequestration of cellular debris into autophagosomes without the use of selective proteins to
bring the debris to the autophagosome. There are three main types of autophagy known as
Chaperone mediated autophagy (CMA), microautophagy, and macroautophagy (8).
Microautophagy was once described as clearly non-specific, working as a phagocytic mass
that engulfed cytoplasmic components without specificity, however it is believed now that
specificity is possible in microautophagy, yet the mechanism has yet to be determined (9).
Chaperone mediated autophagy is more clearly defined than microautophagy but, is different
from macroautophagy in that single proteins are fed across the lysosomal membrane with the
help of chaperon proteins that bind to the target protein. One such example is hsc70 which
binds to a specific motif on the target protein (10, 11). Macroautophagy is most often what is
described when the blanket term autophagy is described (2, 11). Macroautophagy results in
the formation of a double walled membrane around the various degradation targets. For the
purpose of this publication the term autophagy will be used to refer to the process of
macroautophagy.
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1.2 The Process of Autophagy
Autophagy can be described as a five step process that progresses from initiation, to
elongation, to maturation, to autophagosome-lysosome fusion and ends with degradation.
These processes are regulated by autophagy-related genes or Atg (2).
In mammalian cells autophagy results in the formation of double membrane vesicles
mostly from the ER. Ulk1 is a protein that is believed to be involved in this process by
responding to cell stressors such as starvation (2, 12, 13). Ulk1 is a Serine/Threonine kinase
that allows autophagy to begin in response to mTOR deactivation due to cellular stress (26).
It is believed that Ulk1 complex associates with mTOR and Atg13; this complex allows for
mTOR to phosphorylate Ulk1 under nutrient rich conditions (13). Under conditions of
cellular stress, such as nutrient deprivation, mTOR will dissociate from Ulk1 leaving it free
to associate with the ER to initiate formation of the autophagosome (13). At initiation an
omegasome forms in the ER membrane, which produces the beginnings of the phagophore
(14). The exact location of the beginnings of the phagophore is disputed. One site of
initiation is the ER (12). Also involved in the initiation of the membrane formation is
vesicular protein sorting 34 or Vps34. Vps34 complexes with Beclin-1 to increase the ability
of Vps34 to produce high levels of phosphatidyl inositol triphosphate (PI3P) (12). PI3P is
important to the elongation stage and recruiting the other Atg proteins by being recruited to
the ER by Atg14L (12). The elongation process involves Atg7 activating Atg12, transferring
it to Atg10. Atg10 allows Atg12 to link to lysine 130 of Atg5. Atg12-Atg5 complexes with
Atg16L, and is believed to help form the curve of the membrane by later recruiting LC3II
and dissociates once the membrane is formed (12).
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Figure 1.1 Autophagy Pathway, specific to LC3: ATG4 cleaves LC3B, leaving a glycine
residue available, this becomes LC3I. LC3I is activated by ATG7, transferred to ATG3 and
conjugated to PE to become LC3II. LC3I stays in the cytosol. LC3II is then translocated
into the membrane of the autophagosome. This is then degraded in the lysosome. (4)
Microtubule-associated protein light chain 3 (LC3), is normally in the cytosol as a fulllength protein. LC3 is a family of three proteins, LC3A, LC3B and LC3C. LC3B was the
first discovered (31). LC3A and LC3C have less information available. Looking at LC3B
during autophagy, LC3 is cleaved by Atg4 and becomes LC3I. A carboxyterminal glycine is
exposed and is activated by Atg7. Atg3 then conjugates LC3I to phosphatidlyethanolamine
(PE) at the carboxyterminal glycine to form LC3II (12). LC3II is then brought into the
forming membrane by the Atg5-Atg12-Atg16L complex, to continue the elongation cycle.
LC3II is distributed in the membrane and helps with selecting the cargo to go into the
autophagosome and fusion of the membranes (12). The autophagosome combines with the
lysosome to begin the process of degradation of the contents of the autophagosome. After
degradation the degradation products are then recycled back out to the cytosol (12). LC3II in
the cytoplasm has the PE removed by Atg4B, which allows for LC3I to be recycled (2).
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Figure 1.2: The process of Autophagy: From initiation, elongation and maturation, then to
autophagosome-lysosome fusion and lysosome degradation (22).
1.3 Autophagy: Selective or Non-selective
Autophagy was initially thought to be a non-selective process that simply engulfs cellular
debris without concern for the contents. Autophagy is now also known to be a selective
process. Proteins that interact with components of the cell to be removed by autophagy
interact with proteins bound in the autophagosome membrane and providing an anchor
forming autophagosome. The proteins that mediate interaction with LC3 can be known as
autophagy receptors, since they connect with the debris to be removed in the autophagosome.
The interaction occurs through a specific amino acid sequence that is known as the LC3interacting region (LIR) or the LC3 recognition sequence (LRS) (14). One example of
selective autophagy termed aggrephagy involves removal of misfolded or unneeded proteins
by putting them in ubiquitinated aggregates that are attached to the autophagosome for
removal by the lysosome (14). Two known autophagy receptors are p62 and neighbor of
BRCA1 gene (NBR1) which can bind ubiquitinated protein aggregates through an ubiquitin4
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associated domain (UBA) and LC3 through the LIR. The p62 receptor has many other
ubiquinated targets such as bacteria, peroxisomes, damaged mitochondria and viruses (14).
Phosphorylation and ubiquitination play a part in the regulation of selective autophagy such
as in the case of p62 recognizing ubiquitinated protein aggregates and bringing those to the
LC3 in the autophagosome to be degraded by the lysosome. Both NBR1 and p62 are
degraded during autophagy. Suppression of autophagy causes a buildup of p62 in the cells.
Autophagy helps maintain homeostasis in the cells, and the importance of selective
autophagy has become more apparent that as various types of cytosolic debris have been
linked to degradation through autophagy receptors.
1.4 Importance of Autophagy in Disease States
Autophagy has grown as an interest in research concerning disease states such as
different cancer types and neurological disease. Cells use autophagy to maintain homeostasis,
under normal conditions this allows the cells to remain viable, thus enabling them to stave off
apoptosis. It has been found that in cancerous cells autophagy is also used to maintain cells
that may otherwise be sent to death, in the low oxygen and low nutrient environment.
Autophagy can work for the cell to survive a type of cell death that is initiated when the cell
detaches from the extracellular matrix, called anoikis (16). Autophagy is a way for the cancer
cells to survive and metastasize in the increased presence of blood flow enabled by
angiogenesis or rather the process of vascularization to a tumor (16).
Autophagy is also used to target cancer cells, through the use of autophagy inhibiting
chemotherapeutic agents to destroy the tumors by inhibiting the autophagy survival
mechanisms (16). It has been shown that autophagy takes part in cell death induction in
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apoptosis capable cells and it becomes the main death inducing pathway in apoptosis
deficient cells (16).
Autophagy appears to be impaired in neurodegenerative diseases such as Parkinsons and
Alzheimers disease. In Alzheimers and Parkinsons disease autophagosomes accumulate and
there are endosomal-lysosomal abnormalities found in Alzheimers disease (4). Deficiencies
in autophagy and the resulting inability to remove the misfolded proteins may contribute to
neurological disease.
Autophagy may also contribute in other diseases such as cardiovascular disease and
diabetes. In heart disease autophagy may play either a protective role or may contribute to
cell death by either preserving cells that are damaged enabling salvage of the cells or by
pushing cells to apoptosis after extended or overproducing autophagy (27). In type 2 diabetes
impaired autophagy is indicated in

cells, where ubiquitinated proteins accumulate, the

mitochondria are swollen and the ER is distended (24).
1.5 LC3 as a Marker for Autophagy
Microtubule-associated protein 1 light chain 3 (MAP1 LC3) is very commonly noted in
papers concerning autophagy as a process or autophagy in diseased cells. Up regulation of
LC3 can serve as a marker for autophagy. LC3 localization within the cell also serves to
monitor the progression of autophagy. In autophagy, the carboxy-terminal region of LC3 is
cleaved off exposing a glycine residue forming LC3I. LC3I is then modified with a
phosphatidylethanolamine (PE) to form LC3II. The LC3II becomes bound in the inner and
outer membrane of the autophagosome. This process allows for the autophagosome
formation to be monitored and therefore LC3 becomes an important marker to study
autophagy. LC3I is a cytosolic form of LC3 that is soluble. As mentioned before LC3II is
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membrane anchored through its PE modification. These differences allow for the separation
of LC3I and LC3II through cellular fractionation. Western blotting is a method that can be
used to show that autophagy has been activated and usually with an increase in LC3II. LC3
can be tracked using fluorescent microscopy to show the autophagosome formation. The use
of fractionated lysates is also valuable to the study of autophagy. Currently the antibodies
used to study autophagy are insufficient or not useful. Development of antibody that binds
specifically to LC3I and LC3II would enable researchers to separately detect both forms of
LC3 proteins in western blotting and immunohistochemistry. Both antibodies would also
enable the development of ELISA to quantify LC3 levels in biological samples.
1.6 Conclusion
Autophagy is a contributor in maintaining homeostasis within the cells. Autophagy
provides a mechanism for cell survival and cell death. During cellular stressors cell survival
is extended through autophagy, yet may lead to apoptosis if extended for long periods of time
or if overproduced in cells. Autophagy is responsible for the degradation of mis-folded
proteins, damaged or old organelles, bacteria and viruses. Autophagy was originally thought
to be a non-selective process. Certain types of autophagy are considered non-selective;
autophagy is also a selective process. In selective autophagy proteins that have a region
called the LC3 interacting region select the protein or cellular debris and anchor it in the
autophagosome. The autophagosome selects the protein or cellular debris and anchors it in
the autophagosome. The autophagosome then fuses with the lysosome for degradation of the
cargo. Autophagy can enable diseased cells to survive and grow through the stress of a
condition such as in cancer. In other diseases autophagy is impaired and resulting in
accumulation of cellular debris leading loss of cell function. LC3 is an important autophagy
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marker in that it can be used to follow and analyze the selection of protein and cellular
structures into the autophagy pathway and to the formation of autophagosomes within the
cells. Products for analyzing autophagy and more specifically LC3 can be improved. New
reagents and assays are envisioned to aid the researcher in the further understanding of the
role of autophagy in health and disease.
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Chapter 2: Autophagy Processes Enable Production of LC3II Specific Lysate
2.1 Introduction
Autophagy is a tightly controlled process of degradation within the cell, enabling the cell
to mitigate stress and maintain homeostasis. Autophagy can be induced by the following
conditions: nutrient deprivation, infection, hypoxia and by treatment with chemical inhibitors of
the proteins within the pathway (2, 8). Autophagy pathway research includes many disease
states, such as cancer (1), diabetes, cystic fibrosis and cardiovascular disease. Autophagy
research also includes its role in immunity (2). Autophagy activation/dysfunction is found in
diseases that produce protein aggregates, such as Huntington’s, Parkinson’s and Alzheimer’s.
The ability to detect LC3 proteins and differentiate different LC3 Protein derivatives is
important for the advancement of autophagy research. At this time we are looking at LC3
products to produce in order to be able to separate and reveal quantitative differences between
the two LC3 proteins found approaching the end of autophagy, LC3I and LC3II. LC3I is known
to be found at 18kDa and LC3II is known to be found at 18kDa, due to the positive charged PE
which changes the charge of the protein and therefore runs faster on the gel.
Chloroquine is a lysomotrophic drug that is most notably used as an antimalarial
drug and is being researched as a tumor treatment. Chloroquine is a late stage autophagy
inhibitor, shown to cause accumulation of autophagic vacuoles. This effect is thought to be the
result of the choloroquine on the lysosomes pH, it causes the acidic lysosomes to be basic and
therefore lack the degradation properties. By preventing degradation chloroquine treatment
causes the termination of autophagy after the formation of the autophagolysosome. With the
accumulation of autophagolysosomes the cells eventually enter apoptosis.
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The ability to be able to produce a lysate that is singular in either form of the protein is
invaluable to being able to quantitate the separate proteins and perhaps be able to tell levels and
stage of autophagy within the cell sample where the cells are in late stage autophagy. The
intention of my project was to create a protocol for isolating the membrane fraction of cells that
would be easy for researchers/customers. I have used chloroquine in order to activate autophagy
in cells leading to an accumulation of LC3II, in order to harvest the cells, fractionate the lysate
and obtain LC3II rich lysates. Cancer cell lines have been chosen, from different organisms, as it
is known that cancer cells use autophagy to survive (16). The protocol would not require the use
of an ultracentrifuge and could be provided in a kit format. We intend to use this protocol to
isolate LC3II from cells to create a cell lysate that can be sold and to be used as a control in an
immunoassay kit. To produce such lysates cells would have to be induced to enter autophagy and
stalled before reaching lysosome fusion prior to degradation. Techniques for the separation of
LC3II and also LC3I are described herein.
2.2 Materials and Methods
2.2.1 Cell culture
Cell lines Neuro 2A, HeLa and 3T3 were from ATCC and cultured in DMEM (Gibco,
Life Technologies, Grand Haven NY) with 10% fetal bovine serum (PAA, Dartmouth, MA) and
penicillin/streptomycin (Gibco, Life Technologies, Grand Haven NY, USA). RatC6 cells were
from ATCC and were cultured with 10% Horse Serum (Sigma, St. Louis, MO, USA), 2.5% fetal
bovine serum and penicillin/streptomycin. SH-SY5Y cells were from ATCC and were cultured
in DMEM+F12K (Gibco, Life Technologies, Grand Haven, NY, USA) with 10% fetal bovine
serum and penicillin/streptomycin. All cells were kept in a 37oC incubator with 5% CO2. All
cells were plated into 15cm plates.
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Cells were treated with chloroquine (Sigma, St. Louis, MO,USA) at a concentration of
100 M once the plates were approximately 70-75% confluent. After addition of the chloroquine
to fresh media the plates were returned to the incubator for four hours. Plates that were not
treated were also returned to the incubator after a media change. After four hours the cells were
removed from the plates using trypsin (Gibco, Life Technologies, Grand Haven, NY, USA). Cell
pellets were collected in 50mL conical centrifuge tubes and centrifuged at 800rpm. Cell pellets
were then frozen down at -20oC.
2.2.2 Lysate Fractionation
Cell pellets were thawed on ice, buffer A was added and the pellet resuspended (28). This
suspension was rotated at 4oC for 10 mins. Then it was centrifuged at 2000xg for 10 mins at 4oC.
This supernatant was saved and labeled as the cytosol fraction. The pellet was then washed with
0.5mL 1X PBS twice. The remaining pellet was suspended in buffer B (28) and incubated on ice
for 30 mins with vortexing every 5 mins. This was then centrifuged at 7000xg for 10 mins at
4oC. This supernatant was then saved and labeled as the membrane fraction (28). Protein
concentration was determined using the BioRad DC Protein Assay (Hercules, CA, USA).
2.2.3 Western Blotting
Cytosol and membrane fraction lysates were mixed with NuPAGE LDS sample buffer
(Life Technologies, Grand Haven, NY) and 1M DTT (Sigma, St. Louis, MO,USA) and boiled
for 10 mins in a heat block. They were then loaded onto an 18% Tris-HCl Criterion SDS-PAGE
gel (BioRad, Richmond, CA) and transferred by tank transfer to a Protran nitrocellulose
membrane, 0.45 M (Whatman, Piscataway, NJ). Membranes were blocked overnight at 4oC on a
rocker with 5% Non-fat milk and PBS+0.05%Tween20. Following the transfer the membranes
were blotted with two clones of LC3B, mAb (5F10) and LC3B, mAb (2G6) primary antibodies
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(Enzo Life Sciences, Farmingdale, NY, USA). Secondary antibodies were goat anti-mouse HRP
conjugates (Jackson Immunoresearch Laboratory, West Grove, PA, USA). The signal was
detected using enhanced chemiluminescence western blotting detection system (Thermo
Scientific, Rockford, IL, USA).
2.3 Results
2.3.1 Cell Lysate Fractionation and Protein Concentrations
The initial protocol used 1x106 or 2x106 cells/mL of each lysate buffer, and resulted in
protein concentrations below 1.0 mg/mL. Protein concentrations below 1.0 mg/mL do not
provide enough protein in the cytosol fraction to allow LC3 detection by western blotting.
Protein concentrations at or above 2.0mg/mL provide sufficient protein for detection of LC3.
Initial attempts to detect LC3 in the cytosol fractions were unsuccessful, suggesting a change to
the protocol. (This is shown in Figure 2.2 below).

Figure 2.1: Membrane fractions of Neuro 2a (lanes 1-5) and HeLa (Lanes 6-9) cell lysates.
Lanes 2 and 6 show 1x106cells/mL for the control lysate and lanes 3 and 7 show
2x106cells/mL for the control lysate. Lanes 4 and 8 show 1x106cells/mL for the drug treated
lysate and lanes 5 and 9 show 2x106cells/mL for the chloroquine treated lysate. Lane 1 is
the molecular weight marker. Using LC3B, mAb (5F10).
The first attempt to optimize the protocol was to use half the amount of lysis buffer in
order to increase protein concentrations in the cytosolic fraction. Decreasing the amount of
buffer in the lysis procedure enabled preparation of a control lysate for the membrane fraction.
The membrane fraction control lysate was used to further improve the procedure.
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To further improve performance of the western blots, the number of Neuro 2a cells were
increased to enable the detection of LC3 through volume present. The increased cell contribution
enabled the detection of LC3 in both the cytosolic and membrane fractions. The resulting
protocol allowed preparation of a control lysate with protein concentration of 2.0 mg/mL for use
in later experiments. The protocol was successful in fractionating HeLa cells; however LC3
detection was less intense in western.
2.3.2 Use of Different Detergents in Lysate Buffer
Fractionated lysates were initially made with the use of the detergent Detergent A alone
and in combination of Detergent B, to determine if the detergents together would better
fractionate LC3I in the cytosol and LC3II in the membrane fraction. Previous experiments
increasing or decreasing the concentration of detergent in lysis buffers made with single
detergents did not make a difference. When combining Detergent A and Detergent B for lysis of
Neuro 2a cells a large difference in fractionation was observed when compared to single
detergents. Detergent A alone in lysis buffer provided more complete fractionation when
compared to combining Detergent A with Detergent B. The addition of Detergent B causes
LC3I to appear in the membrane fraction rather than maintain segregation in the cytosol. This
was completed in HeLa cells and Neuro 2a cells and is illustrated below by Neuro 2 a cells. The
results were confirmed in both Neuro 2a cells and HeLa cells (Fig. 2.2).
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Figure 2.2: Lysate fractionation of Neuro 2a cells with different detergent additions in
control cells and chloroquine treated cells with 1x10 6cells and 2x106cells: A.) Detergent A and
Detergent B Cytosol Fraction; B.) Detergent A and Detergent B Membrane Fraction; C.) Detergent
A Cytosol Fraction; D.) Detergent A Membrane Fraction. Lane 1: MW Marker, Lane 2: 1x10 6 cells
control, Lane 3: 1x106 cells treated, Lane 4: 2x106 cells control, Lane 5: 2x106 cells treated. Using
LC3B, mAb (5F10)

2.3.3 Western Blotting to Detect LC3 Lysate Fractionation
Western blotting was used to determine if the lysates prepared previously had properly
fractionated during the lysate procedure. LC3I is expected in the cytosol fraction only, while
LC3II is expected in the membrane fraction only. Fractionation was also tested using several
different cell types. Fractionation of LC3I and LC3II could be found in Neuro 2a cells (Figure
2.3), 3T3 cells (Figure 2.3) and HeLa Cells. HeLa cells also produced a fractionated lysate,
however LC3 levels were generally lower resulting in less intense bands by western. 3T3 cells
produced a lysate that was fractionated in the drug treated lysate. 3T3 control cell lysates had
LC3I in the membrane fraction, suggesting that the fractionation was not complete for this cell
line, or at least in the control lysate condition.
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Figure 2.3: Complete Fractionation of LC3I and LC3II in Neuro 2a cells (left) and 3T3 Cells (right).
Western Blotting of Neuro 2a and 3T3 cell fractionated lysate with LC3B, mAb (5F10) antibody.
Lane 1: MW Marker, Lane 2: Cytosol Control Lysate, Lane 3: Cytosol +Chloroquine Lysate, Lane 4:
Membrane Control Lysate, Lane 5: Membrane+Chloroquine Lysate. LC3I is found at 18kDa and
LC3II is found at 16kDa. Using LC3B, mAb (5F10)
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Figure 2.4: Lack of Fractionation of LC3I and LC3II in SH-SY5Y cells (left) and Rat C6 Cells
(right). Western Blotting of SH-SY5Y and Rat C6 cell fractionated lysate with LC3B, mAb (5F10)
antibody.
Lane 1: MW Marker, Lane 2: Cytosol Control Lysate, Lane 3: Cytosol +Chloroquine Lysate, Lane 4:
Membrane Control Lysate, Lane 5: Membrane+Chloroquine Lysate. LC3I is found at 18kDa and
LC3II is found at 16kDa.

A complete lack of autophagy activation or fractionation was found in SH-SY5Y cells and
C6 cells. SH-SY5Y cell fractionated lysates showed only LC3I (figure 2.4) throughout several
attempts and this was in all fractions. C6 cell fractioned lysates also showed only LC3I (figure
2.4) through several attempts at fractionation and the initial attempts actually produced no signal
for LC3 in western blot (not shown).
2.4 Conclusions
It is possible to utilize the lysate fraction procedure using two detergent containing
buffers to produce fractionated lysates without the use of an ultracentrifuge, in different cell
types. The procedure is easy to follow and understand. The procedure may need to be further
optimized in order to eliminate “carry over” of LC3I into the membrane fractions. SH-SY5Y and
C6 cells may not participate in autophagy as much as other cell types, therefore treatment with
chloroquine would be futile. Experiments indicate control lysates in sample buffer at 2.0mg/mL
15
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can be consistently produced and at a reasonable cost. The fractionation procedure only adds one
more step when compared to other control lysates that are produced as Enzo Life Sciences
Products. The simple protocol is suitable for use in a kit and could be included in a total LC3 kit
to allow for LC3II specificity.
2.5 Discussion
The production of fractionated lysates specifically containing LC3II may not be easily
achieved in all cell types. A possible solution to working through this for researchers with
interests other than HeLa, Neuro 2a or 3T3 cells may be to transfect LC3II into the cells of
choice in order to produce the increase in LC3II. However, the control lysates successfully
produced can be used as a control for this same researcher to test their transfection results.
Another treatment could be used in conjuction with chloroquine to first initiate autophagy and
then stop autophagy at the autophagolysosome stage. In working to produce antibodies for LC3I
and LC3II these lysates will be instrumental in showing if a specific antibody will show a
positive result in the cytosol, as would be expected in LC3I, or in the membrane fraction, as
would be expected in LC3II. A control lysate for western blotting could be made using the Neuro
2a fractionated cell lysate. This lysate could be easily reproduced as a manufacturing method.
The protocol that has been set up is simple and could be followed by anyone with a
scientific background. Unlike other fractionation methods, the protocol does not require the use
of an ultracentrifuge, and makes the method useful in more laboratories. The procedure is simple
enough to provide a sample fractionation protocol to be included in assay kits. Enzo Life
Sciences intends to develop ELISA kit that can detect LC3I and/or LC3II specifically. The two
fractionation buffers can be included to enable the differential detections of LC3I and LC3II.
Such an assay will provide a powerful quantitative tool for autophagy research.
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Chapter 3: LC3I and LC3II Monoclonal Antibody Development for the Production of an
LC3I and LC3II Specific Product
3.1 Introduction
The immune system protects the body from foreign organisms that invade it. The immune
system has to be able to distinguish between viruses and the body’s own healthy tissue. The
specificity of the immune response is provided by proteins and cells circulating the body.
Different mechanisms contribute to the immune response and can be put into two divisions,
adaptive immunity and non-adaptive immunity (29). The immune response is not enhanced with
repeated exposures to foreign organisms (29). Non-adaptive immunity reacts the same way to
foreign material every time it comes into contact with it (29). Adaptive immunity provides an
enhanced response with repeated exposures (29). Examples of non-adaptive immunity include
macrophages and natural killer cells and their direct destruction of offending organisms (29).
Adaptive immunity uses lymphocytes which manufacture cell surface receptors or secrete
proteins that bind to the foreign organisms (29). One of the secreted protein types are antibodies.
Antibodies bind to foreign organisms, neutralize them or mark them for removal by other cell
types (29). Any molecule that can be bound by an antibody is called an antigen (29). Any
molecule that is used to induce the immune response is known as an immunogen (29).
The molecular structure of antibodies can be described as Y-shaped (29). Each antibody
is made up of two copies of a polypeptide called heavy chains and two polypeptides called light
chains (29). There are five classes of antibodies, IgG, IgM, IgA, IgE, and IgD (29). The classes
differ in function and structure mostly driven by the type of heavy chain polypeptide and the
number of immunoglobulin structures covalently associated (29). IgG antibodies have a single
immunoglobulin structure and are the most abundant in serum (29). Each arm of the
immunoglobulin structure has an antigen binding site, making the molecule bivalent (29). The
two arms of the immunoglobulin structure are domains known as Fab domains, for fragments
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that are antigen binding (29). There is a third domain that is made up of the bottom of the two
heavy chains and this is known as the Fc domain, for fragment that crystallizes (29). The area
between these is called the hinge and allows for movement to be able to bind different antigen
configurations (29). The two heavy chains in the antibody are identical and are about 55kDa. The
two light chains are also identical and are about 22kDa (29). The four chains are held together by
disulfide bridges and noncovalent bonds (29). The other classes of immunoglobulins are
described in Figure 3.1.
Component
Heavy Chain
Light Chain
# of Y units
Conc. In Serum

IgG
gamma
kappa or
lambda
1
8-16 mg/mL

IgM
mu
k or l

IgA
alpha
k or l

IgE
epsilon
k or l

5
1,2 or 3
1
0.5-2
1-4 mg/mL 10-400 ng/mL
mg/mL
Table 3.1: Classes and Characteristics of Immunoglobulin classes (29)

IgD
delta
k or l
1
0-0.4 mg/mL

Monoclonal antibodies are antibodies that are specifically produced by a clonal cell
population such that each antibody molecule in a given preparation is identical (29). These
antibodies are highly useful when it comes to research methods such as ELISA, western blot,
immunoprecipitation, and immunohistochemistry. Monoclonal antibodies are produced using
hybridoma cells (29). Hybridoma cells are created through the fusion of myeloma cells and
plasma B lymphocytes from the spleen of mice which have been immunized with a specific
antigen (29). After fusion, the cells are then transferred to HAT (hypoxanthine-aminopterinthymidine) media. Aminopterin blocks DNA de novo synthesis preventing survival of myeloma
cells that have not fused with B cells (29). The myeloma cells do not survive because die because
they cannot produce nucleotides using the salvage pathway (29). B cells that have not fused will
die due to a short lifespan (29). Hybridomas are immortal because they inherit the myeloma cells
ability to replicate along with the B cell ability to use the salvage pathway (29). The hybrids or
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Hybridoma cells are grown up and serial diluted into 96-well plates in order to get to achieve
concentrations of a single cell per well. The plates are then incubated to allow cell growth
checked for antibody production by immunoassay. Cells producing antibody are selected and
grown up in larger culture. This process is termed limited dilution cloning and can be done at
least a couple of times to ensure that the resulting antibody is “monoclonal” or from a single
clone (29). Hybridomas can continue to be grown in cell culture and the antibody can be purified
from the tissue culture supernatants. The hybridomas can also be grown in cell culture and then
injected into the peritoneal cavity of mice (29). Growth within the peritoneal cavity will cause
the formation of ascites fluid rich in concentration of the antibody (29). Antibodies can be
purified from the ascites fluid once it is harvested from the mice.
Monoclonals that specifically bind for the LC3I and LC3II, late autophagy, proteins
specifically would be a valuable resource in the growing research interest of autophagy.
Autophagy is becoming more significant in the study of many diseases including cancer, diabetes
and cardiovascular disease. While there are LC3I specific antibodies on the market we believe
that we can create a superior and preferred antibody, this along with being able to create the
antibody at Enzo Life Sciences to be sold as a product. An LC3II specific antibody would be
very beneficial for direct detection of autophagy induction LC3I specific monoclonal antibodies
would be useful in determining where the cells are in the process of autophagy.
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Figure 3.1: A Comparison of LC3 Proteins with the Immunogens: Full LC3 Protein, shown
in 1, LC3I Whole Protein shown in 2 and LC3II Peptide shown in 3. Mklsv is removed to
form the LC3I whole protein.
In order to achieve a monoclonal antibody to LC3I and LC3II, LC3I recombinant whole
protein and a peptide for LC3II were selected as the antigens. Mice at the University of Michigan
were immunized with the antigen linked to the carrier protein KLH on a schedule. Two separate
test bleeds from the tail of the mice were taken and tested against the antigen plated on a
multiwell plate to check for the mouse with the best antibody titer, or rather the best antibody
response. The mouse with the best titer was then euthanized and the spleen cells were used to
make the hybridoma. Cells were grown and the hybridoma supernatants were then tested against
the same antigen. The supernatants that tested positive were selected and the cells brought to
Enzo Life Sciences to be grown and undergo serial dilution cloning to select the best clones to
expand. The selected hybridomas were then grown and transferred gradually to a serum free
media to be grown in disposable bioreactor flasks. The supernatants were harvested from the
disposable bioreactors and stored at -20oC. The harvested supernatants were purified on Protein
G columns. The IgG concentration of each antibody preparation was determined by absorbance
at 280nm. Fractions containing concentrations of at least 1.0 mg/mL of IgG were retained and
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were dialyzed against 1X PBS. The final concentration of the antibody was again determined by
absorbance. The final antibody preparation was tested using previously prepared lysates to show
the detection of LC3I and LC3II by western blot.
3.2 Materials and Methods
3.2.1 Immunogen Selection and Immunization Schedule

Proteins and peptides were chosen for LC3I and LC3II to serve as immunogens. Three, 6
week old Balb/c mice were injected with 10 g, 20 g and 50 g of each immunogen. These
immunogens were mixed with Freund’s adjuvant, the initial intraperitoneal injection was
complete Freund’s and the following injections were incomplete Freund’s. Two weeks after the
initial injection a second injection is given to the mice. One week after this a tail bleed is taken.
Four weeks after the second injection a third injection is given, one week after this injection
another tail bleed is taken. The tail bleeds were screened in ELISA against the LC3I or LC3II
immunogens for the mouse showing the best response to the antigen. The mouse which showed
the best response to the antigen was given a final tail vein boost. (Note: All animal work was
completed by the Hybridoma Core at University of Michigan.)

3.2.2 Cell Culture
Hybridoma cells were cultured in IMDM (Gibco, Life Technologies, Grand Haven, NY,
USA) with 20% fetal bovine serum (PAA, Dartmouth, MA, USA), 5% BriClone (QED
Bioscience Inc., San Diego, CA, USA) and penicillin/streptomycin (Gibco, Life Technologies,
Grand Haven NY, USA). For initial cloning purposes additions of HAT Media Supplement (50x)
Hybri-Max (Sigma-Aldrich, St. Louis, MO, USA) was added and later changed to HT Media
Supplement (50X) Hybri-Max (Sigma-Aldrich, St. Louis, MO, USA) after hybridoma out
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growth. Cells were then adapted to standard media additions of 15% fetal bovine serum (PAA,
Dartmouth, MA,USA) with penicillin/streptomycin (Gibco, Life Technologies, Grand Haven
NY, USA). For antibody production, cells were adapted to PFHM II Media (Gibco, Life
Technologies, Grand Haven, NY, USA) and put into the disposable bioreactor or CELLINE
Integra flasks (Integra Biosciences, New Haven, NH). (Note: All work completed at Enzo Life
Sciences by me.)
3.2.3 Hybridoma Clone Selection using ELISA
Ninety six-well plates (Corning, Corning, NY,USA) were coated with either LC3I-BSA
conjugate protein or LC3II-BSA protein conjugate (Enzo Life Sciences, Farmingdale, NY,USA)
at a concentration of 0.1 g/well overnight at 4oC. The plates were blocked with an assay buffer
(PBS, 0.05% Tween 20, 0.1% BSA) solution at approximately 200 L/well and incubated at
room temperature for 1 hour. One hundred

L of each hybridoma supernatant was added to

separate wells and incubated for 1 hour at room temperature. Peroxidase-conjugated Affinipure
Goat anti-Mouse IgG Fc Fragment specific (Jackson Immuno Research Laboratories, West
Grove, PA, USA) was used as a secondary antibody at a dilution of 1:2000 and incubated at
room temperature for 1 hour. TMB substrate (Neogen, Lexington, KY, USA) was added to the
plate and allowed to develop at room temperature for approximately 20 minutes. HCl (1N) was
added to stop the development and after this the plate was read at 450nM on a
spectrophotometer. (Note: All work completed at Enzo Life Sciences by me.)
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3.2.4 Antibody Isotyping and SDS-PAGE Charaterization
Antibodies were characterized using a mouse specific isotyping kit (AbD Serotec, Inc,
Raleigh, NC). The kit provides developer vials with anti-mouse lambda and anti-mouse kappa in
blue micro particles as well as strips that have immobilized goat anti-mouse antibodies that are
synonymous with typical mouse antibody isotypes. Common antibody isotypes are IgG1, IgG2a,
IgG2b, IgG3, IgM, and IgA. There are also immobilized goat anti-mouse antibodies to lambda
and kappa light chains. The antibody sample can be in tissue culture supernatant, ascites, or
purified.
Antibodies were further characterized by SDS-PAGE on Tris-HCl Criterion Gel (BioRad,
Richmond, CA, USA) at 1 g and 5 g for each antibody. The gel was then stained with Imperial
Protein Stain (Thermo Scientific, Rockford, IL, USA) for 1hr at room temperature on a shaker,
and then destained with dH2O overnight on the shaker at room temperature. (Note: All work
completed at Enzo Life Sciences by me.)
3.2.5 Antibody Purification
Supernatants were collected from the disposable bioreactor, filtered and then frozen at
−20oC. Drip columns were made using a 50% slurry Protein G resin (Pierce, Rockford, IL, USA)
packed with 2mLs of resin. Protein G IgG binding buffer (Pierce, Rockford, IL, USA) was
mixed 50:50 with the cell culture supernatant, centrifuged, filtered and added to the column, the
flow through was saved. Binding buffer was used to wash the column until the wash registered
below 0.05 mg/mL on the nanodrop spectrophotometer. IgG Elution buffer (Pierce, Rockford,
IL, USA) was used to elute the antibody into 10 fractions each containing 100 L of 1M Tris, pH
9.0 neutralizing buffer. The fractions were tested for IgG concentration by absorbance at 280nm.
All fractions that were 1.0 mg/mL and above were collected and combined. The combined
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fractions were dialyzed overnight at 4oC in 3L of 1X PBS. A final concentration, after dialysis
and syringe filtration, was determined by absorbance at 280nm. (Note: All work completed at
Enzo Life Sciences by me.)
3.2.6 Western Blotting
Neuro 2a fractionated cell lysates were separated by SDS-PAGE using 18% Tris-HCl
Criterion Gels (BioRad, Richmond, CA, USA). These gels were transferred to Protran
nitrocellulose membrane, 0.45 M (Whatman, Pistcataway, NJ, USA) through tank transfer.
Membranes were blocked with 5% non-fat milk and PBS+0.05%Tween20 solution overnight at
4oC on a rocker. Several dilutions of the purified antibodies were used to determine the most
effective concentration for the primary antibodies. Monoclonal antibody LC3B 5F10 (Enzo Life
Sciences, Farmingdale, NY, USA) was used as a control antibody to determine the effectiveness
of the newly developed antibodies. Secondary antibodies were goat anti-mouse HRP conjugates
(Jackson Immuno Research Laboratories, Bar Harbor, Maine, USA). The signal was detected
using enhanced chemiluminescent western blotting detection system (Thermo Scientific,
Rockford, IL, USA). (Note: All work completed at Enzo Life Sciences by me.)
3.3 Results
3.3.1 Tail Bleed Screen
A tail bleed screening ELISA was completed with the LC3II immunized mice, one mouse
was selected however, on the day that the mouse was to be euthanized for hybridoma fusion, the
final LC3II mouse was found dead. The bleed results can be found in Figure 3.1. The final LC3II
fusion was performed with excess spleen cells left over and frozen during the first LC3II fusion.
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Figure 3.2: Mouse 3 Bleed Results. This graph shows titer data for mouse 3 against LC3II
peptide-PE. The mouse has a titer at approx. 32000 or 1/32000, which was the cutoff
concentration considered significant.
3.3.2 LC3I and LC3II Clone Selection and Subcloning
For LC3I, six plates were used to perform the initial hybridoma screen and nine clones
were pulled from these plates for OD readings that were at least double the background,
determined using media, PBS, and secondary only blanks. These nine clones were moved to a
24-well plate to grow a larger amount of cells. These were then screened in the same manner and
five of those clones were moved on to limiting dilution subcloning in a 96-well plate to try to
obtain outgrowth from a single cell that produces the antibody and assure a monoclonal culture.
The clones that grew in the wells were again screened with ELISA and determined to not be
reactive. The 24-well clones that these had come from tested positive and were subcloned again,
using limiting dilution. None of the resulting clones produced antibody detectable in the
screening assay.
The final mouse for LC3I was euthanized and the fusions were again screened, this
fusion produced 140 clones that showed high OD readings and were pulled to a 24-well plate to
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expand. The 140 clones were screened again and the highest eight clones were pulled for limiting
dilution in a 96-well plate. The subclones were screened along with the supernatants from the 24well cultures to confirm the subclones maintained the same reactivity to the antigen. The positive
clones were found to have decreased signal relative to the 24-well culture supernatant. Two
clones from the subcloning were found to have a high OD in the screening assay. These were
subcloned again; upon the second subcloning no reactivity was found. Another attempt at
subcloning was attempted and one subclone was found to provide a high OD, but it did not
maintain reactivity once grown in larger culture.
In the LC3II project, the first clones were all producing very high OD readings, such that
no differentiation between any of the clones was possible. Subcloning was completed and again,
all of the supernatants from the clones produced the same high readings. The results indicated
nonspecific binding in our screening assay. To improve specificity, we performed a test with the
ELISA to determine if a blocking buffer change needed to be made in our ELISA screen.
Blocking the plates had previously been eliminated from the procedure due to stable OD
readings in LC3I plates without blocking; a blocking comparison study was designed. It was also
determined that PBS, instead of an assay buffer, was used inconsistently with the secondary
antibody at times. It was determined that using PBS instead of an assay buffer largely increases
the background in the secondary only and the media only blanks.
Once we had re-optimized the assay the LC3II clones from the second fusion were tested
and five clones were selected and subcloned. Two of the parent clones had subclones that tested
positive in the screening ELISA. After a second subcloning five of these were expanded to be
transferred to our regular IMDM hybridoma media. This is shown in Figure 3.3 below.
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Figure 3.3: LC3II Clones from Parent Clone to Subclones: The above graph shows the
initial parent clones after fusion, 2C9 and 2C10, through the first and second subcloning.
After each subcloning the cells gain another number in the naming process.

3.3.3 Isotype of LC3 Antibodies
All LC3 antibodies were characterized by their isotype, using supernatants collected from
disposable bioreactor flasks, which were diluted 1:1000 in a 1% BSA solution. Once mixed in
the developer tube, the strips were added to the tube and allowed to sit for 5-10 minutes. The
antibody isotypes are indicated in table 3.2.
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Antibody

Heavy Chain

Light Chain

LC3II 2C9.13.5

IgG1

Kappa

LC3II 2C9.14.14

IgG1

Kappa

LC3II 2C9.14.2

IgG1

Kappa

LC3II 2C9.14.3

IgG1

Kappa

LC3II 2C10.6.12

IgG1

Kappa

LC3I 6C5

IgG3b

Kappa

LC3I 1A3

IgG3b

Kappa

Table 3.2: Isotypes of LC3 Antibodies
3.3.4 LC3II Supernatant Purification
The five LC3II subclones were transferred to disposable bioreactors after they were stepwise transferred to a serum free hybridoma media. Supernatants were collected from the
bioreactor and saved at -20oC until they were thawed for purification. Out of the five subclones
four were found to have met or exceeded1.0 mg/mL and were kept. The concentrations of the
fractions and their final concentrations after dialysis can be found in Table 3.3.
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Fraction #
1
2
3
4
5
6
7
8
9
10

2C9.14.3
0.01
0.00
0.17
0.44
0.50
0.40
0.28
0.18
0.14
0.10

Volume of Culture Supe Purified

x

Volume after Dialysis

x

Conc. After Dialysis

x

Total Conc. Of Antibody

x

2C9.13.5
2C10.6.12
2C9.14.2
2C9.14.14
0.01
0.00
-0.12
0.04
0.01
0.01
0.00
0.08
0.00
0.37
0.03
3.26
0.58
2.56
1.65
6.56
4.22
2.68
2.42
5.00
4.14
2.14
1.85
2.59
2.74
0.99
1.23
1.20
1.55
0.59
0.76
0.68
0.84
0.26
0.39
0.37
0.47
0.18
0.30
0.29
63.5 mL
12 mL
9.5 mL
31.5 mL
4.25 mL
3.5mL
3.5 mL
5 mL
3.05mg/mL 1.98 mg/mL 1.59 mg/mL 3.53 mg/mL
12.96 mg
6.93 mg
5.56 mg
17.65 mg

Table 3.3: Antibody Concentrations for LC3II Hybridomas. Four of the five clones
produced IgG levels that were about 1.0 mg/mL, these are highlighted, which were saved
and dialyzed in PBS, concentrations were determined using a nanodrop
spectrophotometer.
The four LC3II clones, that produced the most purified antibody, were analyzed for
purity by SDS-PAGE on a 4-15% Tris-HCl Criterion Gel at concentrations of 1 g and 5 g. This
gel was then stained with Imperial Protein Stain and found to have both the heavy chain and light
chains at the approximate molecular weights of 55kDa for the heavy chain and 22kDa for the
light chain. This is shown in Figure 3.4.
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Figure 3.4:Characterization of LC3II Antibodies using SDS-PAGE. 1 represents LC3II
2C9.13.5, 2: LC3II 2C10.6.12, 3: LC3II 2C9.14.2, 4: LC3II 2C9.14.14
3.3.5 LC3 II Western Blotting
The four LC3II antibodies were diluted to 1.0 mg/mL and used at several different
subsequent dilutions in a western blot of the Neuro 2a fractionated lysate that was previously
prepared. Each antibody was tested at dilutions of 1:250, 1:500 and 1:1000. Western blots
included the positive control antibody used previously, mAb (5F10). The control antibody
detected LC3II in all experiments. None of the LC3II antibodies were capable of detecting LC3II
in the western blots. Another attempt was made with Neuro 2a fractionated lysates blocking the
blot with 2% BSA and using BSA to incubate the primary and secondary antibodies; this was
also unsuccessful producing no reaction. Previously made HeLa Fractionated lysates were also
tested with the new LC3II antibodies and the control antibody. Again, the antibodies did not
detect LC3II in the western blots.
3.4 Conclusion
The LC3I monoclonal antibodies have been developed. Initial screening assays showed
LC3I reactivity. LC3I hybridomas have been difficult to stabilize in culture. Instability of
hybridoma cells could contribute to non-producing cells outgrowing producing cells and losing
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LC3I reactivity. The LC3I project will continue through different subcloning techniques to
determine if stability can be achieved.
LC3II monoclonal antibodies were developed. LC3II hybridomas were screened and
subcloned. LC3II antibodies have not been found to react in western blotting. LC3II antibodies
may recognize the peptide but, not the intact protein.
3.5 Discussion
The attempt at development of LC3 monoclonal antibodies has been unsuccessful. In the
time following the fusion of spleen cells and myeloma cells, the newly formed hybridomas can
be unstable. Hybridomas can stop making antibodies during the subcloning process, when cells
that don’t produce antibody may outgrow the antibody producing clones. Subcloning is the most
important and challenging stage of hybridoma development (29), if successful it results in stable
antibody producing cells. LC3I antibody development will continue through further subcloning
using the two previously frozen clones that were previously known to produce LC3I specific
antibodies. We will test those for current LC3I reactivity and expand the positive cultures.
Expanded cells will be considered for antibody production and were frozen down to preserve the
cells. Cells were sent to The University of Michigan for subcloning by their hybridoma core for
subcloning, additionally the cells will be subcloned at Enzo Life Sciences using a semi-solid
media. The semi-solid media enables subcloning by colony selection and achieves subcloning in
a single round. All subclones will then be considered for ascites production in mice to accelerate
antibody production.
The LC3II development was initially much more successful when compared to the LC3I
development. The subcloning was successful and produced clones that had reactivity with the
LC3II peptide in ELISA. For at least four of the five clones of LC3II, there was a substantial
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amount of antibody purified from the cell culture supernatant. This was however unsuccessful at
producing a result in western blot.
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ABSTRACT
LC3I and LC3II as Autphagy Markers for the Development and Improvement of Products
and Techniques used in Research
by
Caitlin J. Williams
August 2013
Advisor: Dr. Robert Akins
Major: Biochemistry & Molecular Biology
Degree: Master of Science
Autophagy is an intracellular process that functions to maintain homeostasis in the cell by
degrading misfolded proteins, old or nonfunctioning organelles, and outside invaders such as
bacteria or viruses. This process can be split into three different types, microautophagy,
chaperone mediated autophagy and macroautophagy. Macroautophagy is the most commonly
studied form and is believed to be regulated by Atg proteins, as well as cargo proteins that bring
debris to the autophagosome. Macroautophagy is characterized by 5 steps including initiation,
elongation, maturation, autophagosome-lysosome fusion and lysosome degradation. Autophagy
has been found to be involved in diseases, such as cancer and neurological disease. LC3I and
LC3II function in late stage autophagy before lysosome fusion. The study of a complex process
such as autophagy requires the development of tools to enable precise and quantitative research.
The ability to produce antibodies to key autophagy proteins, methods of cellular fractionation
and fractionated control cell lysates provides product development opportunities for Enzo Life
sciences and new research tools for researchers. To support these needs, methods of cell
fractionation were developed along with antibodies specific to LC3I and LC3II. Cell
fractionation methods were optimized to enable separation of LC3I and LC3II. The optimized
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methods were shown to be effective on multiple cell lines with the use of western blotting. Due
to the difficulty in achieving stable hybridomas monoclonal antibodies that bind both LC3I and
LC3II haven’t been identified. The LC3II antibody development failed to produce antibodies in
western blotting. Efforts are ongoing to identify stable hybridomas producing antibodies to LC3.
The antibodies should recognize both LC3I and II. Combining the use of these antibodies with
fractionated cell lysate methodology should allow quantitative detection of LC3II by ELISA.
Such a tool will be an important tool for autophagy researchers.
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